Principal Financial Group Inc. Purchases 2,126 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Principal Financial Group Inc. grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,501 shares of the medical research company’s stock after buying an additional 2,126 shares during the period. Principal Financial Group Inc. owned 0.12% of Charles River Laboratories International worth $11,917,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Tortoise Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International in the 3rd quarter valued at $32,000. Assetmark Inc. grew its position in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Charles River Laboratories International in the third quarter worth $59,000. Finally, Covestor Ltd raised its position in shares of Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after buying an additional 95 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on CRL shares. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Robert W. Baird dropped their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, Redburn Atlantic started coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Trading Down 0.3 %

CRL stock opened at $186.16 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The firm’s 50-day moving average is $193.06 and its 200 day moving average is $201.17. The company has a market capitalization of $9.52 billion, a PE ratio of 23.30, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the prior year, the company earned $2.72 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Buying and Selling

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).